Friday, September 1, 2017

MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) a Dark Horse in the Race to Treat Alzheimer’s

Alzheimer’s is the most expensive disease in the United States, and pharmaceutical companies are racing to find viable treatments for this devastating disease, which currently affects more than 5.3 million Americans and their loved ones. Wall Street is placing bets on who will win the race to treat Alzheimer’s, and India Globalization Capital (NYSE MKT: IGC) is one promising candidate with a compelling patent-pending treatment protocol. An excerpt from an article further discussing this reads: “IGC is a pioneer in the development of new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patented and patent pending therapeutics includes treatments for pain, post-traumatic stress disorder, cachexia, neurologic disorders, Parkinson’s, and, now, Alzheimer’s disease. IGC recently acquired the exclusive rights to its novel THC-based treatment for Alzheimer’s disease from the University of South Florida (http://www.igcinc.us/alzheimers-disease/). The patent identifies discovery of a new pathway in which low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is exactly what occurs in Alzheimer’s disease and causes cognitive decline.”

To view the full article, visit http://dtn.fm/Orm8S

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html